 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN, a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Companys first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology ASH Annual Meeting. The presentations are available at Our imetelstat presentations at this years 